What Justice Ginsburg’s Death Means For Pharma
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
You may also be interested in...
Judge Jackson’s Patent, FDA Rulings Show She Is ‘Super Smart’ And Would Be Beneficial For Pharma
Supreme Court nominee issued three decisions on Hatch-Waxman regime as district court judge, including case in which she ruled against the FDA’s denial of orphan drug designation and another in which she deferred to the agency’s view on exclusivity. Her analysis of facts may play a role if the court takes up a case on administrative agency deference.
Drug Pricing Day At The US Supreme Court
Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.
Biden's Drug Pricing Administrative Actions Could Focus On Medicare Demos
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.